- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04060277
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of CMV-MVA Triplex Vaccine in Adult Recipients of Haploidentical Hematopoietic Stem Cell Transplant
Study Overview
Status
Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Acute Myeloid Leukemia
- Hodgkin Lymphoma
- Myelofibrosis
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Chronic Lymphocytic Leukemia
- Non-Hodgkin Lymphoma
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine if CMV-MVA multi-peptide CMV-modified vaccinia Ankara vaccine (Triplex) reduces the frequency of clinically significant CMV reactivation in CMV positive (+) haploidentical hematopoietic cell transplantation (haploHCT) adult recipients from when letermovir (Prevymis) prophylaxis is stopped at day (d)100 until d180 post HCT.
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerability of Triplex in vaccinated, haploHCT recipients by assessing the following: non-relapse mortality (NRM) at d180 post-HCT, severe (grade 3-4) acute graft versus host disease (GVHD), and grade 3-4 adverse events (AEs) (Common Terminology Criteria for Adverse Events [CTCAE] 5.0) probably or definitely related to the vaccination within 2 weeks from each vaccination at d180 post-HCT.
II. To characterize CMV related events in recipients of Triplex compared to placebo, by assessing time-to viremia (number of days from d100 to the date of >= 625 IU/mL), duration of viremia, recurrence of viremia, incidence of late CMV viremia/disease (>= 625 IU/mL, > 200 and =< 365 days post-HCT), use of antiviral drugs (triggered by clinically significant viremia), cumulative number of CMV specific antiviral treatment days.
III. To evaluate the impact of Triplex on transplant related outcomes up to d365 post-HCT by assessing the incidence of acute GVHD (aGVHD), chronic GVHD (cGVHD), relapse, non-relapse mortality, all-cause mortality, infections.
IV. To determine if Triplex increases levels, function and kinetics of CMV-specific T cell immunity in vaccinated compared to placebo treated, CMV seropositive HCT-recipients.
V. To determine whether vaccination induces adaptive natural killer (NK) cell population changes, and increase in the highly cytotoxic memory NKG2C+ NK cells.
VI. To compare GVHD biomarkers between the vaccine and placebo groups up to d365 post-HCT.
VII. To determine if immunity to 3 CMV antigens contained in the Triplex vaccine correlates with protection against CMV events, and if T-cell increases reflect vaccine response and exceed placebo immune response levels up to d365 post-HCT.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive letermovir per standard of care (SOC) on days 7-100 and multi-peptide CMV-modified vaccinia Ankara vaccine intramuscularly (IM) on days 100 and 128 post-HCT.
ARM II: Patients receive letermovir per SOC on days 7-100 and placebo IM on days 100 and 128 post-HCT.
After completion of study treatment, patients are followed up to 365 days post-HCT and then for an additional 2 years post-HCT.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All subjects must have the ability to understand and the willingness to sign a written informed consent
- Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT
Planned peripheral blood stem cell (PBSC) or bone marrow (BM) HCT for the treatment of the following hematologic malignancies:
- Lymphoma (Hodgkin and non-Hodgkin)
- Myelodysplastic syndrome
- Acute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia/lymphoblastic lymphoma, the disease status must be in hematologic remission by bone marrow and peripheral blood. Persistent lymphadenopathy on computed tomography [CT] or CT/positron emission tomography [PET] scan without progression is allowed.)
- Acute myeloid leukemia in first or second remission
- Chronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase
Other hematologic malignancies judged appropriate by the clinical principal investigators (PIs), including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis. Patients with multiple myeloma and those with non-malignant disease such as aplastic anemia are excluded
- Adult cases of multiple myeloma (MM) are excluded as HCT is not standard of care for MM, and is only performed in very advanced cases with an associated high risk of relapse and NRM. Adults with aplastic anemia are excluded because their standard management includes T cell depletion with agents such as anti-thymocyte globulin (ATG), which is not permissible on this protocol. Patients undergoing a second haploHCT are not eligible (patients who have undergone a previous autologous HCT are eligible)
- Patients receiving myeloablative (MA) or reduced intensity conditioning (RIC) are allowed
- CMV seropositive (recipient)
- Planned related HCT with molecular 3/6 (haploidentical) intermediate/high resolution HLA donor allele matching
- Planned HCT with minimal to no-T cell depletion of graft
- Conditioning and immunosuppressive regimens according to institutional guidelines are permitted
- Negative serum or urine beta human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration
- Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within 2 months of registration and no history of disseminated cutaneous human papillomavirus (HPV) related disease
- Agreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for up to d90 post-HCT. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
Exclusion Criteria:
- Any prior investigational CMV vaccine
- Experimental anti-CMV chemotherapy in the last 6 months
- Live attenuated vaccines (from the time of HCT to d70 post-HCT)
- Medically indicated subunit (Engerix-B for HBV; Gardasil for HPV) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections) (from the time of HCT to d70 post-HCT)
- Allergy treatment with antigen injections (from the time of HCT to d70 post-HCT)
- Alemtuzumab or any equivalent in vivo T-cell depleting agent (or CD34+ selection) (from the time of HCT to d70 post-HCT)
- Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)/valganciclovir (VAL), foscarnet (FOS), cidofovir, CMX-001, maribavir. Acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV) (from the time of HCT to d70 post-HCT)
- Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment EXCEPT Prevymis prophylaxis (prior to d100) (from the time of HCT to d70 post-HCT)
- Conditioning regimens d30 prior to trial participation and up to d180 post-HCT
- Disease-based radiation therapy (not total body irradiation) (from the time of HCT to d70 post-HCT)
- Other investigational product - concurrent enrollment in other clinical trials using any investigational new drugs (IND) with unknown effects on CMV or with unknown toxicity profiles is prohibited (from the time of HCT to d70 post-HCT)
- Other medications that might interfere with the evaluation of the investigational product (from the time of HCT to d70 post-HCT)
- Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible
- Patients considered by PIs/protocol team to have a complicated prior therapy or HCT regimen, or who have a low survival probability (e.g., refractory leukemia and/or undergoing 2nd HCT)
- Poor risk disease/disease status including: chronic myeloid leukemia (CML) in blast crisis, acute myeloid leukemia (AML)/acute lymphoblastic leukemia (ALL) beyond 2nd remission, multiple myeloma, and aplastic anemia
- Pregnant women and women who are lactating. Triplex risks to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the administered vaccine, also breastfeeding should be discontinued if the mother is enrolled on this study
- Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/ psychological issues, etc.
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (letermovir, Triplex)
Patients receive letermovir per SOC on days 7-100 and multi-peptide CMV-modified vaccinia Ankara vaccine IM on days 100 and 128 post-HCT.
|
Given as SOC
Other Names:
Given IM
Other Names:
|
Active Comparator: Arm II (letermovir, placebo)
Patients receive letermovir per SOC on days 7-100 and placebo IM on days 100 and 128 post-HCT.
|
Given as SOC
Other Names:
Given IM
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinically significant cytomegalovirus (CMV) reactivation prompting antiviral therapy or CMV disease
Time Frame: From first injection to days 100 and 180 post-hematopoietic stem cell transplant (HCT)
|
Will be defined by histology.
Will compare vaccine and placebo regarding cumulative incidence of CMV events from first injection to day 180 post HCT using Gray's test.
|
From first injection to days 100 and 180 post-hematopoietic stem cell transplant (HCT)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-relapse mortality
Time Frame: At 365 days post-HCT
|
Cumulative incidence curves and Gray's test will be used.
|
At 365 days post-HCT
|
Severe (grade 3-4) acute graft versus host disease (GVHD)
Time Frame: Up to day 365 post-HCT
|
Up to day 365 post-HCT
|
|
Grade 3-4 adverse events
Time Frame: Up to 365 days post-HCT
|
Adverse events probably or definitely related to the vaccination and modified vaccinia Ankara vector persistence will be evaluated.
Final analysis of HCT-recipients safety will be based on comparison of vaccine and placebo regarding severe GVHD, immune reconstitution, and survival.
Comparisons will be made using standard methods for right-censored data with interim analysis using standard group-sequential testing.
Will plan a 2^0 analysis comparing event-free survival in both arms.
|
Up to 365 days post-HCT
|
Duration of viremia
Time Frame: Up to day 200 post-HCT
|
Repeated measures analyses will be used.
|
Up to day 200 post-HCT
|
Duration of anti-CMV therapy
Time Frame: Up to day 200 post-HCT
|
Repeated measures analyses will be used.
|
Up to day 200 post-HCT
|
Peak CMV polymerase chain reaction value
Time Frame: Up to day 200 post-HCT
|
Repeated measures analyses will be used.
|
Up to day 200 post-HCT
|
Recurrence of CMV viremia
Time Frame: Up to day 200 post-HCT
|
Repeated measures analyses will be used.
|
Up to day 200 post-HCT
|
Incidence of late CMV reactivation or disease
Time Frame: At day 365
|
Repeated measures analyses will be used.
|
At day 365
|
Time to engraftment
Time Frame: At day 365
|
At day 365
|
|
Incidence of acute GVHD
Time Frame: At day 365
|
Cumulative incidence curves and Gray's test will be used.
|
At day 365
|
Incidence of chronic GVHD
Time Frame: At day 365
|
Cumulative incidence curves and Gray's test will be used.
|
At day 365
|
Relapse
Time Frame: At day 365
|
Cumulative incidence curves and Gray's test will be used.
|
At day 365
|
Non-relapse mortality
Time Frame: At day 365
|
Cumulative incidence curves and Gray's test will be used.
|
At day 365
|
All-cause mortality
Time Frame: At day 365
|
At day 365
|
|
Infections
Time Frame: At day 365
|
Cumulative incidence curves and Gray's test will be used.
|
At day 365
|
Overall survival
Time Frame: At day 365
|
Will be compared using Kaplan-Meier curves and log-rank test.
|
At day 365
|
Levels and kinetics of CMV-specific T cell immunity
Time Frame: At day 365
|
Levels and kinetics of CMV-specific T cell immunity combined with immunophenotyping and functional studies will be evaluated.
|
At day 365
|
Natural killer phenotype and function (cytotoxicity and cytokine production)
Time Frame: At day 365
|
At day 365
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ryotaro Nakamura, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Leukemia, Lymphoid
- Leukemia, B-Cell
- Chronic Disease
- Neoplasms
- Lymphoma
- Myelodysplastic Syndromes
- Leukemia
- Leukemia, Myeloid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Leukemia, Myeloid, Accelerated Phase
- Myeloproliferative Disorders
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Vaccines
- Letermovir
- Acetic Acid
Other Study ID Numbers
- 19065 (Other Identifier: City of Hope Comprehensive Cancer Center)
- NCI-2019-04888 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic and Lymphoid Cell Neoplasm
-
University of California, San FranciscoLazarex Cancer FoundationTerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant NeoplasmUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
Clinical Trials on Letermovir
-
The First Affiliated Hospital of Soochow UniversityRecruitingHematopoietic Stem Cell Transplantation | CMV InfectionChina
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus (CMV) InfectionUnited States, Australia, Colombia, France, Germany, Israel, Japan, Mexico, Poland, Spain, Turkey
-
National Institute of Allergy and Infectious Diseases...Merck Sharp & Dohme LLCCompletedHIV Infections | Cytomegalovirus | CMVUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus Infection | Cytomegalovirus DiseaseJapan
-
University Medical Centre LjubljanaRecruiting
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingCytomegalovirus InfectionFrance
-
Maimónides Biomedical Research Institute of CórdobaMERCK SHARP & DOHME DE ESPAÑA S.A.Not yet recruitingInfections, CytomegalovirusSpain
-
Memorial Sloan Kettering Cancer CenterMerck Sharp & Dohme LLCRecruitingCMV | CMV Infection | Hematopoietic Cell TransplantUnited States
-
University of PennsylvaniaMerck Sharp & Dohme LLCNot yet recruitingCytomegalovirus Infections | Transplant-Related DisorderUnited States
-
Virginia Commonwealth UniversityMerck Sharp & Dohme LLCRecruitingCMV | Kidney Transplant; ComplicationsUnited States